
Indications: Ixazomib, in combination with lenalidomide and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least one prior line of therapy.
Usage Restrictions: Ixazomib is not recommended for use during the maintenance treatment phase, nor is it recommended to use ixazomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma outside of controlled clinical trials.
from FDA,2024.07
Ixazomib is indicated for the treatment of multiple myeloma, a type of bone marrow cancer. Its mecha···【more】
Recommended:232026-07-01
Ixazomib is a second-generation proteasome inhibitor that has emerged as a pivotal therapeutic optio···【more】
Recommended:242026-07-01
Ixazomib is indicated for the treatment of multiple myeloma, a type of bone marrow cancer. Its mechanism of action involves inhibiting a protein that drives the growth and prolifer···【more】
Article source:Lucius LaosRelease date:2026-01-07Recommended:23
Ixazomib is a second-generation proteasome inhibitor that has emerged as a pivotal therapeutic option for the treatment of multiple myeloma.What are the indications of Ixazomib?Ixa···【more】
Article source:Lucius LaosRelease date:2026-01-07Recommended:24
Ixazomab is suitable for the treatment of multiple myeloma.【more】
Article source:Lucius LaosRelease date:2026-01-06Recommended:17

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: